Oncohema Key

Fig. 10.1 Type I and type II FLT3 inhibitors. The binding of FL to the extracellular domain of wild-type FLT3 leads to its dimerization, stabilizing a conformation in an active…

Fig. 15.1 Metabolism of purine nucleotides 15.2 Forodesine Forodesine [BCX-1777, immucillin-H, 7-[(2S,3S,4R,5R)-3,4-dihydroxy-5-hydroxymethyl-2-pyrrolidinyl]-1,5-dihydro-4H-pyrrolo-[3,2-d]-pyrimidin-4-one, monohydrochloride] is a transition-state analog that potently inhibits PNP enzyme activity (Fig. 15.2) [12–15]. Forodesine has shown anticancer…

Fig. 5.1 Chimeric structure of rituximab. Rituximab is a chimeric anti-CD20 monoclonal antibody containing human IgG1 heavy chain and human kappa light chain constant regions and murine immunoglobulin heavy and…

Fig. 14.1 The chemical structures of nelarabine and ara-G. (a) Nelarabine. (b) Ara-G 14.2 Mechanisms of Action 14.2.1 Mechanisms of Action (Fig. 14.2) In the blood, nelarabine is rapidly demethoxylated…

Fig. 8.1 Blinatumomab has anti-CD19 single-chain Fv (scFv) fragment at N-terminal and anti-CD3 scFv fragment at C-terminal. Each scFv is composed of V light chain and V heavy chain. Each…